. Author manuscript; available in PMC: 2021 Feb 1.

Published in final edited form as: Transpl Int. 2019 Oct 29;33(2):113–127. doi: 10.1111/tri.13504

Table 4.

Registered clinical trials of tolDCreg or regulatory macrophages in living donor kidney or liver transplantation

Cell type^*	Organ transplant K (kidney); L (liver)	Type of trial	Target cell dose (range)	Trial ID	Recruitment status (# patients)
TolDC
Autologous, blood monocyte-derived tolDC	K	Phase I/II	10⁶/kg	University of Nantes (ONE STUDY)	Completed (11)
Donor blood monocyte-derived tolDC	K	Phase I	0.5–5×10⁶/kg (dose escalation)	University of Pittsburgh	Recruiting (14)
Donor blood monocyte-derived tolDC	L	Phase I/II	2.5–10×10⁶/kg	University of Pittsburgh	Recruiting (14)
^*Regulatory macrophages (Mreg)
Donor blood monocyte-derived regulatory macrophages	K	Phase I/II	2.5–7.5×10⁶/kg	University of Regensburg (ONE STUDY)	Terminated (8)

Administered before transplantation

In each instance, immunosuppressive therapy comprises prednisone, MPA, and tacrolimus